Related Experiment Video
Updated: Aug 29, 2026
Skeletal Muscle Neurovascular Coupling, Oxidative Capacity, and Microvascular Function with 'One Stop Shop' Near-infrared Spectroscopy
Published on: February 20, 2018
Technology evaluation: Onyvax-105, Onyvax
1Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA. rblumenthal@gscancer.org
Abstract:
Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000.
Insights
Onyvax-105 is an investigational anti-idiotype monoclonal antibody therapy for colorectal cancer. Phase II clinical trials commenced in May 2000 to evaluate its therapeutic potential.
Area of Science:
- Oncology
- Immunotherapy
- Monoclonal Antibody Development
Background:
- Colorectal cancer remains a significant global health challenge.
- Novel therapeutic strategies are continuously being explored to improve patient outcomes.
- Anti-idiotype antibodies represent a promising class of targeted therapies.
Purpose of the Study:
- To evaluate the safety and efficacy of Onyvax-105 (105AD7) in patients with colorectal cancer.
- To assess the potential of Onyvax-105 as a targeted immunotherapy.
- To advance the development of novel colorectal cancer treatments.
Main Methods:
- Development of Onyvax-105, an anti-idiotype monoclonal antibody, under license from the Cancer Research Campaign.
- Initiation of Phase II clinical trials in May 2000.
- Evaluation of therapeutic response and patient tolerance.
Main Results:
- Phase II clinical trials were initiated in May 2000.
- Data on efficacy and safety are pending further trial progression.
Conclusions:
- Onyvax-105 is under investigation as a potential treatment for colorectal cancer.
- The initiation of Phase II trials marks a critical step in its clinical development.
- Further research is necessary to establish its role in colorectal cancer therapy.
